CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
BACKGROUND:T-cell depleting strategies have become an integral part of immunosuppressive regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody against CD52, a cell-surface antigen on several immune cells. It has been suggested that lymphocyte depletion increases the risk...
Main Authors: | Ryuichi Hotta, Masahiro Ohira, Toshiharu Matsuura, Izumi Muraoka, Panagiotis Tryphonopoulos, Ji Fan, Akin Tekin, Gennaro Selvaggi, David Levi, Phillip Ruiz, Camillo Ricordi, Rodrigo Vianna, Hideki Ohdan, Herman Waldmann, Andreas G Tzakis, Seigo Nishida |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4999148?pdf=render |
Similar Items
-
CD52-Negative NK cells are abundant in the liver and less susceptible to alemtuzumab treatment
by: Hotta, R, et al.
Published: (2016) -
Clinical-Scale Isolation of Interleukin-2-Stimulated Liver Natural Killer Cells for Treatment of Liver Transplantation with Hepatocellular Carcinoma
by: Masahiro Ohira, et al.
Published: (2012-07-01) -
Effect of anti-CD52 antibody alemtuzumab on <it>ex-vivo </it>culture of umbilical cord blood stem cells
by: Law Ping, et al.
Published: (2008-10-01) -
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
by: Hale, G, et al.
Published: (2002) -
ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
by: Muthusamy, A, et al.
Published: (2011)